Prostate-specific antigen best practice policy—part I: early detection and diagnosis of prostate cancer - 03/09/11
Doi : 10.1016/S0090-4295(00)00993-6
Peter Carroll a, Christopher Coley b, David McLeod c, Paul Schellhammer d, Greg Sweat e, John Wasson f, Anthony Zietman g, Ian Thompson h, ⁎
a Department of Urology, University of California, San Francisco, Medical Center, San Francisco, California, USA
b Department of Medicine, Harvard University Health Services, Cambridge, Massachusetts, USA
c Department of Urology, Walter Reed Army Medical Center, Washington, DC, USA
d Eastern Virginia Graduate School of Medicine, Norfolk, Virginia, USA
e Department of Family Medicine, Mayo Clinic, Rochester, Minnesota, USA
f Department of Community and Family Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
g Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
h Division of Urology, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, USA
*Reprint requests: Ian Thompson, M.D., Division of Urology, Mail Code 7845, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284
Plan
© 2001
Elsevier Science Inc. Tous droits réservés.
Vol 57 - N° 2
P. 217-224 - février 2001 Retour au numéro
Article précédent
- Interposition sural nerve grafting during radical retropubic prostatectomy
- Edward D Kim, Peter T Scardino, Dov Kadmon, Kevin Slawin, Rahul K Nath
- Prostate-specific antigen best practice policy—part II: prostate cancer staging and post-treatment follow-up
- Peter Carroll, Christopher Coley, David McLeod, Paul Schellhammer, Greg Sweat, John Wasson, Anthony Zietman, Ian Thompson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?